

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Date: 6th August 2025

To,

Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400 001 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No.C/1, G Block Bandra Kurla Complex, Bandra (E) Mumbai-400 051

Dear Madam/Sir,

Sub: Analysts/Investors call

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q1 FY2025-26 Earnings Conference Call, which is to be held on Wednesday, August 13, 2025, at 17.00 hrs.

A copy of this intimation is also being made available at:

https://www.vbshilpa.com/investor-presentation.php

We request you to take the above information on record.

Thanking you.

Yours faithfully, For Shilpa Medicare Limited

Ritu Tiwary Company Secretary



Shilpa Medicare Limited 1QFY26 Earnings Conference Call

Shilpa Medicare Limited (BSE:530549; NSE: SHILPAMED) will announce its results for the first quarter ended June 30, 2025 on Wednesday, August 13, 2025.

Following the announcement, the management of the Company will host its earnings call on Wednesday, August 13, 2025 at 17:00 hrs.

Details of Earnings Conference Call	
Day/Date	Wednesday, August 13, 2025
Time	17:00 hrs
Universal Access	+91 22 6280 1130
	+91 22 7115 8031
The number listed above is universally accessible from all networks and all countries	
International Toll-Free Numbers	
USA	18667462133
UK	08081011573
Singapore	8001012045
Hong Kong	800964448
DiamondPass™ Link	Click here to join with DiamondPass™ (No Wait Time)
Participants are requested to dial-in 10 minutes before the scheduled time	

About Shilpa Medicare Limited (SML)

Shilpa Medicare Limited (SML) is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio. The company also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.

For more information, visit www.vbshilpa.com

For further details, please get in touch with

Shilpa Medicare Ltd Monish Shah E: monish.shah@vbshilpa.com